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ABSTRACT
Among the factors associated with the resurgence of whooping cough, special emphasis has been given to pathogen
adaptation after the introduction of the acellular vaccine (ACV). To assess the impact of the vaccine transition strategy
from whole-cell vaccine (WCV) to ACV on population dynamics of Bordetella pertussis in Barcelona (Spain), we studied
339 isolates collected from 1986 to 2015 by PFGE and multi-locus variable-number tandem repeat analysis (MLVA).
Additionally, allelic variants for the pertussis toxin and its promoter, pertactin, type 3 fimbriae and fimbrial serotyping
were assessed to determine its antigenic drift. A shift was observed in the B. pertussis population as well as in its
antigenic profile concurrently with the introduction of ACV in Barcelona. Four out of the five most prevalent PFGE
profiles were replaced by new profiles following the ACV introduction. MLVA type 27 was the dominant genotype,
and its frequency increased from 25% to 79.3% after WCV replacement. Antigen typing demonstrated the emergence
of prn2, ptxP3, fim3-2 and a shift from the fimbriae 3 to the fimbriae 2 serotypes after the ACV introduction. Our
findings support the presence of population and antigenic dynamic changes in B. pertussis likely driven by the
introduction of ACV.
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Introduction
Whooping cough, or pertussis, is an acute human upper
respiratory tract infection caused byBordetella pertussis,
a highly communicable airborne Gram-negative cocco-
bacillus. The pertussis immunization programme was
first introduced in Spain in 1965, with the adminis-
tration of a whole cell vaccine (WCV). Later, in 1998
an acellular vaccine (ACV) progressively replaced the
WCV vaccination programme with the aim of improv-
ing vaccine safety. Finally, since 2005 ACV is the only
vaccine administered to the Spanish population [1]. In
Catalonia, the vaccination programme against pertussis
follows the same programme (Table 1).
Despite extensive vaccination campaigns and high
immunization rates (86% for global primary vacci-
nation in 2018), the incidence of whooping cough sig-
nificantly reemerged during the first decade of the
twenty-first century, not only in Spain and Europe
but also worldwide. This unfavourable situation has
led to pertussis becoming the leading vaccine-preven-
table disease in industrialized countries, and hence, a
global public health problem [2–5].
Pertussis normally presents a classical cyclic pattern
with epidemic waves occurring every 3–5 years inter-
spersed with periods of a lower incidence rate. How-
ever, at present, the number of cases is higher than in
previous decades [6]. The reemergence of pertussis in
Spain is particularly well supported by recent epide-
miological data. The incidences reported for the inter-
epidemic years from 2001 to 2010 ranged from 0.7 to
1.9 cases/100,000 population. However, despite having
a vaccination coverage of 96.5% in infants younger
than 12 months, the incidence rates observed after
the last two epidemic waves (2011 and 2015) remained
high even during interepidemic periods (>5 cases/
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100,000 population). Of note was the increase reported
during the last epidemic wave in 2015 which showed a
maximum incidence of almost 18 cases/100,000 popu-
lation [7]. The figures reported in Catalonia have fol-
lowed a similar trend albeit with an even more
pronounced progression, with an incidence of 49
cases/100,000 population in 2015 [8].
The resurgence of whooping cough may be related
to increased awareness and improved diagnostic
tools, although the special emphasis has been given
to waning immunity, particularly associated with the
introduction of ACV and pathogen adaptation [9,10].
ACV contains a combination of different antigens
including pertussis toxin (PT), pertactin (PRN) and
filamentous haemagglutinin (FHA), and in some vac-
cines, type 2 and type 3 fimbriae (FIM2 and FIM3)
[2]. Nevertheless, the immunologic protection con-
ferred by ACV is not as enduring as that previously
observed for WCV [11]. The current allelomorphic
profile of the ACV antigens includes ptxA2/ptxA4,
prn1/prn7, fhaB1, fim2-1 and fim3-1 [12]. The natu-
rally-driven antigenic divergence, together with the
impact exerted by the ACV vaccine has likely played
a key role in the selection of new antigenic variants,
which is in keeping with the increased frequencies of
the allelic variants ptxA1, prn2, and fim3-2 seen in
countries where ACV has been extensively used
[2,4,13]. Another bacterial adaptation event associated
with the resurgence of this pathogen is the selection of
a new PT promoter type. In 2009 the new ptxP3 variant
was characterized in relation to increased toxin pro-
duction levels and was shown to have rapidly replaced
the previous predominant ptxP1 allele [14,15].
The main objective of this study was to shed
new light on the impact of the introduction of ACV
on the evolution and adaptation of B. pertussis iso-
lates over a 30-year period in Spain, particularly
those collected in the metropolitan area of Barcelona
before, during and after the WCV replacement by
ACV. This characterization was achieved by molecu-
lar epidemiology analysis of clinical isolates together
with a study of the vaccine antigen variants of the
pathogen.
Materials and methods
Bacterial isolates and study period
A total of 339 non-duplicate B. pertussis clinical isolates
were collected at the Hospital Vall d’Hebron
(Barcelona, Spain). All the isolates were recovered
from cultures of nasopharyngeal samples collected
from patients diagnosed with pertussis, excluding
isolates of the studies of contacts. The isolates were col-
lected from patients with different vaccination status:
vaccinated, unvaccinated and partially vaccinated
(Table S1, Supplementary Information).
The isolates were collected over 30 years, from 1986
to 2015. The study period was divided into three parts
on the basis of the vaccine type/s used for routine vac-
cination in our setting: (i) period 1 (1986–1997; n = 82
isolates) was defined by the single use of WCV; period
2 (1998–2003; n = 82 isolates) was the transition period
as WCV was used only for primary vaccination
whereas ACV was used in boosters; and period 3
(2007–2015, n = 175 isolates), when ACV completely
replaced WCV. Additionally, 10 previously character-
ized strains (B3313, B1900, B1706, B1917, B2726,
B0366, B0549, B0610, B1916 and B3230) were included
in the present study for comparison in the clonal relat-
edness studies. These strains have been described as
being the most representative clones (PFGE profiles
and MLVA types) circulating in several European
countries during the period 1998–2015 [16–18].
Table 1. Pertussis vaccination programme used in Catalonia (Spain) since 1965.
Primary doses Booster doses
Year
Vaccine
type Schedule Pertussis components
Vaccine
type Schedule Pertussis components
1965 DTPw 2 doses between 3
months and 3 years
Inactivated whole cell NA No booster NA
1967 DTPw 3 doses between 3
months and 3 years
Inactivated whole cell NA No booster NA
1975 DTPw 3, 5, 7 months Inactivated whole cell NA No booster NA
1996 DTPw 2–3, 4–5, 6–7 months Inactivated whole cell DTPw 15–18 months Inactivated whole cell
1998–1999 DTPw 2, 4, 6 months Inactivated whole cell DTPa 18 months 4–6 years PT, FHA, PRN
2000 DTPw/DTPa 2, 4, 6 months Inactivated whole cell or
PT, FHA, PRN
DTPa 18 months 4–6 years PT, FHA, PRN
2002 DTPa 2, 4, 6 months PT, FHA, PRN DTPa 18 months 4–6 years PT, FHA, PRN
2011 DTPa 2, 4, 6 months PT, FHA, PRN DTPa/
dTpa
18 months (DTPa), 4–6
years (dTpa)
PT, FHA, PRN or PT, FHA,
PRN, FIM2, FIM3a
2014 DTPa 2, 4, 6 months PT, FHA, PRN DTPa/
dTpa
18 months (DTPa), 6 years
(dTpa)
PT, FHA, PRN or PT, FHA,
PRN, FIM2, FIM3a
2014b NA NA NA dTpa between 27 through 36
weeks of pregnancy
PT, FHA, PRN or PT, FHA,
PRN, FIM2, FIM3
Notes: NA: not applicable; DTPw: diphtheria-tetanus-whole cell pertussis vaccine; DTPa: diphtheria-tetanus-acellular pertussis vaccine; dTpa: diphtheria-teta-
nus-accellular pertussis vaccine with reduced antigenic load of diphtheria, tetanus and pertussis; PT: pertussis toxin; FHA: filamentous haemagglutinin; PRN:
pertactin; FIM2: type 2 fimbriae; FIM3: type 3 fimbriae. These data have been collected from Campins M, et al ([1] and personal communication).
aThe composition containing pertussis fimbrial antigens is used in some cases for the fifth dose.
bIntroduction of maternal pertussis vaccination.
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Pulsed-field gel electrophoresis (PFGE)
The genetic relatedness of all the B. pertussis isolates
included in the present study was determined using
DNA fingerprint by PFGE, which was performed as
described previously [19]. The DNA fingerprint
profiles were analysed with the GelCompare II v.4.6
software (Applied Maths) using the arithmetic
UPGMA as a group method with a band tolerance of
1% and an optimization setting of 1%. Underrepre-
sented PFGE profiles (n < 5 isolates) were grouped as
“others”.
Multi-locus variable-number tandem repeat
analysis (MLVA)
Strain relatedness was also studied using MLVA typing
analysis as described previously [20]. A subset of repre-
sentative strains belonging to different PFGE profiles
and time periods was selected for our MLVA compari-
son (n = 72). Accordingly, one isolate was selected from
each of the less representative PFGE profiles (29 PFGE
profiles, 29 isolates). For the most prevalent PFGE
profiles (9 PFGE profiles, 43 isolates), 3 isolates were
selected from each time period (1 from the beginning,
one from the middle and 1 from the end of each
period). In the case of PFGE profiles partially rep-
resented in a time period, available isolates were
selected. Each locus was amplified by PCR and the
resulting fragments analysed as described previously
[20]. MLVA types (MT) were assigned using the
MLVA typing tool (https://www.mlva.net/bpertussis/
default.asp).
Antigenic variants
A total of 231 strains belonging to different PFGE
profiles were included in the characterization of anti-
genic variants: a subset of representative strains (n =
56) was selected for periods 1 and 2 whereas all strains
collected during period 3 were analysed (n = 175).
Among the genes encoding virulence factors included
in the ACV, the A subunit of the pertussis toxin
(ptxA), pertactin (prn) and type 3 fimbriae (fim3)
were studied using PCR-based sequencing as described
previously [21,22]. Additionally, the promoter type of
pertussis toxin (ptxP) was also studied [14].
Fimbrial serotyping
Fimbriae 2 (FIM2) and 3 (FIM3) serotyping of all 339
B. pertussis isolates included in the present study were
performed by the indirect ELISA method as described
previously [23,24]. Monoclonal antibodies (06/124;
FIM2, and 06/128; FIM3) were obtained from the
National Institute for Biological Standards and Control
(NIBSC) and the reference strains Tohama I (FIM2),
B1900 (FIM3) and B3313 (FIM2 and FIM3) were
used as positive controls.
Statistical analysis
PFGE profiles and MLVA types diversity were calcu-
lated based on the ratio between the PFGE profiles or
MLVA types identified by the total number of isolates.
The Simpson diversity index (SDI) was calculated based
on the formula SDI = 1− Σn(n− 1)/N(N− 1) where n
indicates the number of individual PFGE profiles or
MLVA types identified and N indicates the number of
all PFGE profiles or MLVA types observed [18].
Results
Study periods
All the isolates recovered in the present study (n = 339)
were grouped into three study periods taking into
account the gradual WCV replacement: period 1
(1986–1997, n = 82) was defined as WCV adminis-
tration alone; period 2 (1998–2003, n = 82) was the
vaccine transition period, and period 3 (2007–2015,
n = 175) was characterized as exclusive ACV
administration.
Molecular typing: PFGE
The genetic relatedness of the 339 isolates was evalu-
ated by PFGE. The results identified a total of 38 differ-
ent PFGE profiles (Table S1, Supplementary
Information). Of these, 19, 10 and 18 PFGE profiles
from periods 1, 2 and 3, respectively were identified.
VH2 was the only PFGE profile detected along the
entire period (1986–2015), with a remarkable gap in
the epidemic year 2000 and the following interepi-
demic years 2001–2002 (Figure 1). Additionally, a
replacement of PFGE profiles was observed across the
three periods, being more notable from period 1 to
period 2. In period 1 (1986–1997, WCV) the PFGE
profiles most frequently detected were VH2 (23.2%),
VH8 (17.1%), VH5 (14.6%), VH12 (12.2%) and VH7
(7.3%). The introduction of ACV during period 2
(1998–2003) correlated with the emergence of VH19
(40.2%) and VH20 (36.6%), which were only margin-
ally detected (1.2%) during period 1. Finally, in period
3 (2007–2015, ACV) PFGE profiles VH19 (28.6%),
VH26 (24.6%), VH2 (18.3%) and VH22 (8%) were
the most prevalent. During this last period, VH19
was the most frequent PFGE profile before the epi-
demic year 2011 (from 2007 to 2010, 48.6%; from
2011 to 2015, 15.2%), whereas progressive replacement
by PFGE profiles VH26 and VH2 was observed from
2011 onwards (from 2007 to 2010, 10% and 11.4%,
respectively; from 2011 to 2015, 34.3% and 22.9%,
respectively) (Figure 1).
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The PFGE profiles of clinical isolates obtained
from several European countries from 1998 to 2015
were compared [16–18]. The results showed that
the predominant European PFGE profiles BpSR3,
BpSR5, BpSR10, BpSR11 and BpSR12 were respect-
ively indistinguishable from VH26, VH22, VH2,
VH19 and VH20 reported in this study, (Figure S2,
Supplementary Information). General trends were
similarly observed in both geographical areas (Europe
and Spain) (Table 2): (i) BpSR11 (VH19) was the pre-
dominant profile during the period 1998–2005 (27–
40%) and showed decreased prevalence in recent
years (15–29%); (ii) BpSR10 (VH2) was less prevalent
during the period 1998–2005 but has increased since
2006 (from 8% to 27% in Europe, from 4% to 18% in
Spain); (iii) BpSR5 (VH22) has shown a similar low
prevalence in both studies since its first detection in
1998 (1–11%); and (iv) BpSR3 (VH26) remained
undetected from 1986 to 2003 but rapidly became
one of the most prevalent types during the period
2007–2015 (22–29% in both areas). On the contrary,
the greatest difference was seen for the PFGE profile
BpSR12 (VH20). It was one of the most prevalent
types in Spain (37%) from 1998 to 2003, thereafter
it showed a remarkable decrease (4%) and was only
a minor profile (4–7%) in Europe throughout the
study period.
Molecular typing: MLVA
MLVA typing was performed in 72 isolates selected
as being representative of each PFGE profile (28, 16
and 28 isolates from each period, respectively)
(Table S1, Supplementary Information). Overall, 13
different MLVA types (MTs) were found: 11, 4 and
4 MTs were detected during periods 1, 2 and 3,
respectively. Among these, MT27 was the most preva-
lent type (56.9%) and clearly showed an increasing
frequency: 25% during period 1, 68.8% during period
2 and 79.3% in the third period (Figure 2). Less
representative MTs were MT16, MT28, MT60,
MT70, MT95, MT101 and MT158, which were
detected in more than one isolate with a prevalence
per period ranging from 6.3% to 18.8%. Among
these, MT28 was the only MT detected throughout
the three periods (7.1%, 6.3% and 7.1%, respectively).
The remaining MTs were exclusive of period 1
(MT70, MT16 and MT95), exclusive of period 3
(MT101) or present in both periods 1 and 2 (MT60
and MT158). Finally, five MTs were represented by
Figure 1. Temporal distribution of PFGE profiles of B. pertussis circulating in the metropolitan area of Barcelona from 1986 to 2015.
WCV: Whole cell vaccine; ACV: Acellular vaccine; Bold-face type is used to indicate epidemic years.
Table 2. PFGE profiles of B. pertussis circulating in the metropolitan area of Barcelona from 1986 to 2015 compared to PFGE profiles














2001) n = 102
EUpert II (2004–
2005) n = 154
EUpert III (2007–
2009) n = 140
EUpert IV (2012–
2015) n = 265
VH2 23 4 18 BpSR10 8 10 21 27
VH19 0 40 29 BpSR11 27 30 13 15
VH20 1 37 4 BpSR12 4 7 4 4
VH22 0 1 8 BpSR5 6 8 11 5
VH26 0 0 25 BpSR3 0 8 22 29
Total 24 82 84 Total 45 63 71 80
Note: Values are %.
aThese data have been collected from EUpert studies [16–18].
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single isolates: MT32, MT133, MT135 and MT146
from period 1 and MT30 from period 3 (3.6% indi-
vidual prevalence per period).
Comparative genetic diversity
The comparison of the genetic diversity among the
three study periods based on differences in percentages
of PFGE profiles and MTs showed a gradual decrease
over time (Table 3). Thus, the diversity of the PFGE
profiles identified decreased from 23.2% in period 1,
to 12.2% in period 2, and to 10.3% in period 3. A simi-
lar and more evident decrease was seen for the MLVA-
types, from 39.3% in period 1, to 25% in period 2, and
to 14.3% in period 3. The Simpson’s diversity indexes
calculated for each study period showed no differences
in the transition from WCV to ACV on analysing the
PFGE profiles (0.88 period 1, 0.70 period 2 and 0.82
period 3), whereas differences were noted when
MLVA was taken into consideration (0.89 period 1,
0.52 period 2, and 0.33 period 3).
ACV impact on the evolution of antigen variants
and fimbrial serotype
Allelic variant analysis was carried out in a selection
of isolates to assess the prevalence and evolution of
the most frequently studied vaccine components
(PT, PRN and FIM3) among the B. pertussis popu-
lation from Barcelona over the last 30 years (Figure 3).
The promoter type of the pertussis toxin (ptxP) was
also studied. A total of 231 isolates were analysed
(40 belonging to period 1, 16 to period 2, and 175
to period 3).
Regarding the ptxA gene, our results revealed that all
the isolates analysed carried the ptxA1 allele (Figure 3
(A)). In contrast, an important shift was observed con-
cerning the promoter type. PtxP1 was the most preva-
lent type while WCV was administered (period 1,
87.5%; period 2, 12.5%) but became undetectable
when ACV was the only type of vaccine used in
Spain (period 3) (Figure 3(B)). An inverse correlation
was seen for the new ptxP3 variant associated with
higher PT production levels. It was first detected in
1996 (5%, period 1) and rapidly became the predomi-
nant allele (87.5% and 97.7% for periods 2 and 3,
respectively). This predominance was seen in all the
PFGE profiles analysed with the exception of VH5, a
PFGE profile almost exclusive of period 1, as the only
VH5 isolate collected in 2000 and analysed here har-
boured the ptxP1 variant. Other less prevalent promo-
ter types (2.3–2.5%) were observed in period 1 (ptxP5,
ptxP10 and ptxP11) and period 3 (ptxP15).
The pertactin gene allele distribution proved to be
heterogeneous during period 1. Specifically, prn1 and
prn3 were the most frequently detected (42.5% and
20%, respectively), while a lower frequency of prn2
was detected (3.7%). Nonetheless, the prn2 allele
became the most predominant after the introduction
of ACV, reaching a prevalence of 87.5% in period 2
and 97.7% in period 3 (Figure 3(C)).
Finally, regarding the fim3 genotype, our results
showed that all the isolates studied in period 1 carried
the fim3-1 variant, whereas a similar prevalence of
Figure 2. MLVA types of B. pertussis circulating in the metropolitan area of Barcelona from 1986 to 2015. WCV: Whole cell vaccine;
ACV: Acellular vaccine.
Table 3. Percentage of PFGE profiles and MLVA types
identified and Simpson diversity index calculated for PFGE











PFGE Diversity (%) 23.2 12.2 10.3
Simpson diversity index 0.88 0.70 0.82
MLVA Diversity (%) 39.3 25 14.3
Simpson diversity index 0.89 0.52 0.33
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fim3-1 and fim3-2 variants were detected in periods 2
(43.8% and 56.3%, respectively) and 3 (46.9% and
53.1%, respectively) (Figure 3(D)). Intriguingly, from
2011 onwards fim3-1 showed a progressive reemer-
gence to again become the most predominant variant
over fim3-2 (data not shown). Thus, the 2 most preva-
lent allelic combinations detected in the present study
during the most recent years were defined by isolates
carrying the same allelic composition for ptxA1,
ptxP3 and prn2, while only differing in the allele encod-
ing FIM3 (Figure 4).
Regarding fimbrial serotyping, overall 72.6% of the
isolates had FIM3, 20.9% FIM2 and 3.2% FIM2/3.
Additionally, 11 isolates (3.2%) were deficient for
FIM2 and FIM3. The distribution of the serotypes
per periods revealed that there was a significant
increase of FIM3 isolates during the transition from
WCV to ACV (57.3% during period 1,90.2% during
period 2; P < .05) while FIM2 decreased dramatically
(31.7% during period 1, 0% during period 2; P < .05).
However, once the ACV was completely introduced
(period 3), a progressive decrease of FIM3 isolates
Figure 3. Antigen variants detected in B. pertussis circulating in the metropolitan area of Barcelona from 1986 to 2015. (A) Pertussis
toxin. (B) Pertussis toxin promoter type. (C) Pertactin. (D) Type 3 fimbriae. P1: exclusive use of whole cell vaccine; P2: transition from
whole cell vaccine to acellular vaccine; P3: exclusive use of acellular vaccine.
Figure 4. Temporal evolution of the most prevalent antigenic profiles observed in B. pertussis circulating in the metropolitan area of
Barcelona from 1986 to 2015. Period 1: exclusive use of whole cell vaccine; Period 2: transition from whole cell vaccine to acellular
vaccine; Period 3: exclusive use of acellular vaccine.
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was detected (71.4%) as long as FIM2 isolates gradually
reemerged (25.7%) (Figure 5). During period 1 (WCV),
all FIM2 and FIM3 isolates were associated with a fim3-
1 genotype, while during period 2 (transition from
WCV to ACV) 46.2% and 53.8% of the FIM3 isolates
studied belonged to fim3-1 and fim3-2 genotypes,
respectively. Finally, in period 3 (ACV), all the FIM2
isolates had the fim3-1 genotype while both genotypes
were identified (71.2% fim3-2 and 28.8% fim3-1) for
FIM3 isolates. There was no correlation among sero-
types and vaccinated, non-vaccinated and partially vac-
cinated patients (P > .05).
Combining the analysis of PFGE profiles and
fimbrial serotype, most of the FIM2 isolates belonged
to PFGE profiles VH26 and VH2 (42.3% and 18.3%,
respectively) while most of the FIM3 isolates belonged
to PFGE profiles VH19, VH2 and VH20 (32.1%, 15.4%
and 14.2%, respectively). Regarding the most common
PFGE profiles, isolates belonging to VH2 and VH26
included positive isolates for the FIM2 (24.1% and
69.8%, respectively) and also the FIM3 (70.4% and
27.9%, respectively) serotypes, whereas PFGE profiles
VH19, VH20 and VH22 were almost exclusively
FIM3 (95.2%, 92.1% and 100%, respectively). There
was no significant association between FIM2/3, or
FIM2 and FIM3 deficient isolates and specific PFGE
profiles (Table S1, Supplementary Information).
Discussion
Changes in the B. pertussis population have been
reported worldwide [2–4,13]. Nonetheless, there are
no data related to Spanish strains. In this study, 339
B. pertussis isolates collected in Barcelona during the
period 1986–2015 were analysed to assess the molecu-
lar evolution of this pathogen. Moreover, the global
impact of the vaccine transition strategy from WCV
to ACV was assessed by integrating data from molecu-
lar typing and antigenic variance. The results of this
study show a clear shift in the B. pertussis population
as well as in its antigenic profile concurrent with the
introduction of ACV, as noted in other countries.
Only isolates showing the VH2 PFGE profile were
found to persist throughout the entire study period.
Isolates belonging to PFGE profiles VH8, VH5 and
VH12, which were predominant during the years in
which WCV was the only vaccine administered, were
almost completely replaced by the newly appearing
profiles VH19, VH20 and VH22, which became domi-
nant once ACV remained as the only vaccine in use.
Finally, PFGE profile VH26 appeared in 2007 and
has become the most prevalent profile since 2011.
These results are largely consistent with the most
prevalent PFGE profiles detected in Europe within
the same 30-year time frame [2,16–18]. Our findings
are also in agreement with the predominant PFGE
profiles circulating in the US since 2000 [3]. Overall,
these results reinforce the successful intercountry dis-
semination of B. pertussis lineages not only among
neighbouring countries but also among overseas terri-
tories with similar vaccination policies. However, slight
variations in the prevalence of the distribution of some
PFGE profiles were noted on comparing local and
European isolates. Specifically, the PFGE profile
VH20 was one of the most prevalent types in Barcelona
from 1998 to 2003 (37%) but showed a noteworthy
decrease from 2007 to 2015 (4%). On the contrary,
its equivalent European PFGE profile (BpSR12) was
only a minor profile in Europe during the whole
study period (4–7%). This fact highlights the need for
regional studies to fully understand population
dynamics within and across territories. Probably, the
introduction of whole-genome sequence in future
studies may shed new light on the understanding of
the evolution and rate of lineage mixing within areas.
Next, we assessed whether there are epidemiological
differences between epidemic and inter-epidemic
periods. The percentage of minority PFGE profiles
was clearly increased in the latter, particularly for
period 1 and less pronounced in period 2. It is of inter-
est that the VH12 PFGE profile was only detected
during the epidemic years 1989, 1992 and 1997.
These results suggest that some epidemic waves
might be related to particular clones sharing specific
characteristics, what could contribute to increased dis-
semination potential.
The MLVA results supported the PFGE findings
regarding temporal trends and dynamic changes in
the population structure of B. pertussis in Barcelona
over time. A trend to a lower diversity of MTs was
observed in concurrence with the switch in vaccines,
mainly due to the growing dominance of MT27 (25%
during WCV administration from 1986 to 1997, to
79.3% once ACV was completely implemented). Simi-
lar figures have been reported across Europe as well as
in the US and Australia since the introduction of ACV
[2,13,18,25]. In contrast, the prevalence of MT27 is
Figure 5. Evolution of fimbrial serotypes in B. pertussis isolates
circulating in the metropolitan area of Barcelona from 1986 to
2015. WCV: Whole cell vaccine; ACV: Acellular vaccine.
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marginal in countries in which WCV is still used, or
has been used until only recently, such as in China
(6% in period 2012–2013), Poland (2.9% in period
1959–2013) or the Philippines (not detected) [26–28].
Apart from changes in the bacterial epidemiological
profiles, we also assessed the impact of the introduction
of ACV on the allelic selection of vaccine-related viru-
lence determinants. We found that all the isolates col-
lected across the entire study period were ptxA1, in
agreement with previous reports in which ptxA1 was
described as being the most prevalent variant at the
end of the 1960s immediately after the introduction
of the WCV [9]. Consequently, as the PT variants
included in the ACV are encoded by ptxA2 and
ptxA4 alleles, a protective effect against ptxA1 is no
longer expected.
On the contrary, two remarkable antigenic shifts
were found: the first was related to the new PT promo-
ter variant ptxP3, and the second to the prn2 allele.
Strains carrying the ptxP3 variant have been character-
ized by increased toxin production levels and higher
virulence potential [14]. Moreover, such strains have
been associated with the reemergence of the pathogen
in most parts of the world since the 1990s, concomitant
to a shift towards older age groups [13,14,29]. The
abrupt replacement of ptxP1 by ptxP3 seen in period
2 was paralleled by a similar change in the prevalence
of PRN variants, with prn2 becoming dominant after
almost completely displacing prn1. This is in the line
of previous reports showing a similar shift towards a
clear dominance of the prn2 allele after the introduc-
tion of ACV, which includes the allelic variants prn1
and prn7 which were most frequently detected before
the withdrawal of WCV [9,18].
Lastly, we also completed the antigenic profile of our
isolates by the characterization of the FIM3 genotype,
which is absent in some commercially available
ACVs. To date, two alleles have been reported as
being the most prevalent: fim3-1 and fim3-2. The
results of our study show that all the strains analysed
from period 1 only carried the fim3-1 variant, whereas
a substantial decrease was subsequently observed
towards a similar proportion (43.8% for period 2 and
46.9% for period 3). Nonetheless, since 2011 fim3-1
has shown a progressive reemergence towards the pre-
dominant variant. Similar results have been reported in
Dutch isolates which showed a transitory increased
prevalence of fim3-2 strains which reverted a few
years later [30]. Although overall most of the isolates
were FIM3 (72.6%), on stratifying the results according
to the vaccine administered once ACV was introduced,
a progressive shift from FIM3 to FIM2 was observed,
even though most of ACV compositions used in our
area do not contain any fimbrial antigen (Table 1).
Similar results were reported in different European
countries, such as Denmark and Finland, where ACV
does not contain fimbrial components and FIM2
isolates were the most prevalent from 2012 to 2015.
Conversely, FIM3 isolates were predominant during
the period 2012–2015 in France, United Kingdom
and Sweden, although the ACV contained fimbrial
components only in the first two [18]. Therefore, fac-
tors other than the type of fimbrial antigen contained
in the vaccine may be involved in the serotype shift.
On the other hand, comparing the association of
fimbrial serotype with PFGE profiles we observed
that, as previously found in the EUpert III and IV
studies, isolates belonging to VH19 (BpSR11), VH20
(BpSR12) and VH22 (BpSR5) PFGE profiles were
mostly associated with FIM3 regardless of the period
in which they were isolated. However, during the tran-
sition from WCV to ACV, all VH2 (BpSR10) and
VH26 (BpSR3) isolates were FIM3 while a shift
towards the FIM2 serotype was observed once the
ACV was fully implemented [17,18].
According to the results of the present study, the
alleles detected in the most prevalent isolates circulating
in our population since 2011, and at least until 2015,
were as follows: ptxA1 for the pertussis toxin, which is
regulated by a pxtP3 type promoter, prn2 for pertactin
and fim3-1 for serotype 3 fimbriae. The corresponding
shifts in the antigenic profile of the strains can be par-
tially correlated with PFGE profile replacement, par-
ticularly in period 3: the PFGE profile VH19 (mainly
ptxA1, ptxP3, prn2, fim3-2) has been replaced by
VH26 (mainly ptxA1, ptxP3, prn2, fim3-1). These
results suggest that the absence of uniformity in vaccine
composition has failed to counteract the dissemination
of fim3-1 isolates. Dissemination of VH26 could be sup-
ported by a bacterial advantage provided by this
fimbrial allele or by another virulence trait specific of
this clone. Conversely, VH2 (mainly ptxA1, prn2,
fim3-1) was detected throughout three study periods,
and several factors may have influenced its continuous
detection: no selective pressure on pertactin together
with an inner adaptation ability, highlighting that the
same PFGE profile acquired the widely disseminated
ptxP3 variant. Thus, the adaptative plasticity of
B. pertussis facilitates the diversity and selection of the
most appropriate clones in addition to an evolving abil-
ity to integrate chromosomal changes in the same clone.
In conclusion, these results support the presence of
dynamic changes in the B. pertussis population as well
as in its antigenic profile in Barcelona (Spain) over a
30-year time period, with a trend towards homogeniz-
ation following the introduction of the ACV. Our
findings suggest that the use of the ACV has likely
driven the population changes and antigenic shift of
B. pertussis.
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